Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 15/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 3/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16158285 | 0.80 | AR (0.43) | KDM4EMAPTARPGRNR3C2 | |
| SCHEMBL31243559 | 0.79 | HTR2A (0.46) | ARPGRNR3C2 | |
| SCHEMBL6649345 | 0.79 | ESR1 (0.43) | ARPGRNR3C2 | |
| SCHEMBL7156675 | 0.78 | KDM4E (0.46) | KDM4EMEN1GAAMAPTKMT2A | |
| SCHEMBL23124039 | 0.75 | AR (0.44) | ARPGRNR3C2 | |
| SCHEMBL7154079 | 0.75 | MAPT (0.49) | MEN1MAPTKMT2ATDP1PGR | |
| SCHEMBL29789835 | 0.75 | AR (0.44) | ARPGRNR3C2 | |
| SCHEMBL5331013 | 0.73 | MAPT (0.46) | KDM4EMEN1GAAMAPTKMT2A | |
| SCHEMBL29789709 | 0.73 | MAPT (0.46) | KDM4EMEN1GAAMAPTKMT2A | |
| SCHEMBL23123813 | 0.72 | AR (0.38) | ARPGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186132-A1 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2004-09-23 | — | — | US | disclosed |
| US-6696459-B1 | USING HIGH AFFINITY, HIGH SELECTIVITY QUINOLINE DERIVATIVESW | LIGAND PHARMACEUTICALS INC. | 2004-02-24 | — | — | US | disclosed |
| EP-1382597-A2 | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6667313-B1 | High affinity and specificity | LIGAND PHARMACEUTICALS INC. | 2003-12-23 | — | — | US | disclosed |
| EP-0800519-B1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030149268-A1 | 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators | HAMANN LAWRENCE G (US) | 2003-08-07 | — | — | US | disclosed |
| US-6534516-B1 | Method of affecting androgen receptor activity comprising the in vivo administration of a composition | LIGAND PHARMACEUTICALS INCORPORATED | 2003-03-18 | — | — | US | disclosed |
| US-6448405-B1 | COUPLING A 2-HALO-5-NITROBENZOIC ACID AND A 2-METHOXYPHENYL BORONIC ACID; CYCLIZING TO A NITROBENZOCOUMARIN; REDUCING TO THE AMINE; CONVERTING TO A COUMARINO(3,4-F)QUINOLINE; REDUCTION TO A 5H-CHROMENO(3,4-F)QUINOLINE | LIGAND PHARMACEUTICALS INCORPORATED | 2002-09-10 | — | — | US | disclosed |
| EP-1212322-A2 | 8-SUBSTITUTED-6-TRIFLUOROMETHYL-9-PYRIDO[3,2-G]QUINOLINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-0918774-B9 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARM INC (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-1997049709-A1 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-31 | — | — | WO | disclosed |
| US-5696130-A | Tricyclic steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5696133-A | ADMINISTERING COMPOUND WHICH MODULATES ACTIVITY OF PROGESTERONE RECEPTOR | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5696127-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-09 | — | — | US | disclosed |
| US-5693647-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5693646-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5688808-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| US-5688810-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186132-A1 | Steroid receptor modulator compounds and methods | NR5A1, ESRRA, NR3C2 | KDM4E 3167/4885MEN1 3750/4885GAA 4605/4885 |
| US-20030149268-A1 | 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators | AR, SHBG, NR5A1 | KDM4E 1493/4885MEN1 2750/4885GAA 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.